Combatting COVID-19 – 4Factor on pharma

The race is on in healthcare to combat COVID. Who are the potential winners?

30. Apr. 2020

15 Minuten

At a glance

  • The pharmaceutical industry is not immune from the disruption caused by the coronavirus (COVID-19) pandemic, but for some companies there are also opportunities
  • Testing, drugs that treat symptoms and the provision of necessary equipment could provide a boost for some companies
  • Using technology to track people’s movement or enforce quarantine is another potential weapon in the armoury to combat COVID-19
  • Ultimately finding a vaccine is the only long-term solution to the crisis. Understanding how close we are to a solution that triggers a sustainable recovery is crucial for investors

The coronavirus COVID-19 pandemic has caught the world unawares. Against a background of human tragedy and the interruption of daily life, scientists are moving rapidly to find a solution that will allow normal activity to resume. The biggest push is towards development of a vaccine. Another focus is on finding an effective treatment for symptoms. Scientists are also in pursuit of an antibody test to identify who has already had the disease and is therefore potentially immune. In addition, governments are exploring non-medical disease mitigation, such as the use of social media and tracing to further contain the spread of the virus. Some Asian countries have deployed this technology to increase the effectiveness of social distancing and it may be deployed elsewhere, despite the civil liberty issues.

For investors, these are unprecedented and challenging times with high levels of uncertainty and market volatility to contend with. We explore the latest scientific developments to provide investors with some clarity and context, as well as consider companies that could potentially benefit from a medical breakthrough.


Download PDF

All investments carry the risk of capital loss. The value of investments, and any income generated from them, can fall as well as rise and will be affected by changes in interest rates, currency fluctuations, general market conditions and other political, social and economic developments, as well as by specific matters relating to the assets in which the investment strategy invests. If any currency differs from the investor’s home currency, returns may increase or decrease as a result of currency fluctuations. Past performance is not a reliable indicator of future results.

Verfasst von

Rhynhardt Roodt

Co-Head of 4Factor

Christine Baalham

Portfolio Manager

Jonathan Parker

Portfolio Manager

Joanna Tucka

4Factor analyst

Important Information

This communication is provided for general information only should not be construed as advice.

All the information in is believed to be reliable but may be inaccurate or incomplete. The views are those of the contributor at the time of publication and do not necessary reflect those of Ninety One.

Any opinions stated are honestly held but are not guaranteed and should not be relied upon.

All rights reserved. Issued by Ninety One, issued April 2020.